On December 3, 2025 ImpriMed, a precision oncology CRO specializing in ex vivo drug sensitivity testing for hematologic malignancies, reported that it has been selected to present two significant research studies at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition in Orlando, Florida, taking place December 6-10.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Being featured at ASH (Free ASH Whitepaper) is an important validation of our xCellSense platform for both pharma partners and clinicians," said Sungwon Lim, Chief Executive Officer of ImpriMed. "Our data demonstrates that ex vivo functional testing, combined with genomic profiling, can effectively predict which acute myeloid leukemia (AML) patients will respond to specific therapies. This powerful combination equips drug developers and physicians with the critical evidence needed to select the most effective treatments, design innovative clinical trials, and ultimately improve patient outcomes."

ImpriMed will present data from a prospective study integrating NGS-based genomic profiling with ex vivo drug sensitivity testing across a panel of 21 drugs in AML patients treated with standard-of-care regimens. The data demonstrate that ex vivo drug-sensitivity testing successfully stratified survival risk in AML patients and identified clinically meaningful genotype-drug associations. These results validate the platform’s utility for drug development applications, including lead candidate selection, patient enrichment strategies, and the development of companion diagnostics.

Additionally, the company will share findings on a quantitative ex vivo drug synergy analysis methodology using primary samples from AML patients. This innovative system enables pharmaceutical companies to identify synergistic drug combinations and accurately identify the patient subgroups most likely to benefit from combination therapy.

Oral Presentation Details:

Session: 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology
Date/Time: December 8, 2025, 3:15 PM – 3:30 PM
Publication Number: 939
Title: "Ex vivo drug sensitivity testing in Korean AML patients: Integration of functional and genomic profiles for predicting clinical response and survival"
Poster Presentation Details:

Session: 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster III
Date/Time: December 8, 2025, 6:00 PM – 8:00 PM
Publication Number: 6137
Title: "Quantitative ex vivo synergy profiling uncovers heterogeneous combination responses in AML primary samples"

(Press release, ImpriMed, DEC 3, 2025, View Source [SID1234661115])